EMA Authorised: NovoNorm (repaglinide) — Novo Nordisk A/S

View source ↗

Summary

The EMA authorised NovoNorm (repaglinide) for type 2 diabetes, marking its approval in the European Union.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• NovoNorm (repaglinide)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Novo Nordisk A/S. Decision date: 05/09/2017